{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-016899","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.978184+00:00","generated_at":"2026-06-22T04:12:27.155758+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Olema Pharma Q3 net loss $22.7M; cash $222.6M; OP-1250 shows 41% tumor reduction","bullets":["Net loss $22.7M in Q3 2022 vs $17.7M in Q3 2021; R&D expenses $17.6M GAAP ($14.8M non-GAAP).","Cash, equivalents and marketable securities $222.6M at Sept 30, 2022; sufficient into H2 2024.","OP-1250 monotherapy: 41% of heavily pre-treated patients had tumor reduction; 6 partial responses; Phase 2 fully enrolled.","OP-1250 + palbociclib combo: dose escalation completed, Phase 2 expansion ongoing; no dose-limiting toxicities.","Phase 3 monotherapy study planned for mid-2023; FDA Fast Track granted for ER+/HER2- metastatic breast cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-016899","json":"https://secwatch.observer/filing/0001558370-22-016899.json","markdown":"https://secwatch.observer/filing/0001558370-22-016899.md","text":"https://secwatch.observer/filing/0001558370-22-016899.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000155837022016899/0001558370-22-016899-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000155837022016899/olma-20221108x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:12:27.155758+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"161cce298011845f73392d39844750678d1fc722","claim":"Olema Pharmaceuticals, Inc. reported the quarter ended September 30, 2022 results: net income $22.7 million.","evidence_excerpt":"Net loss for the quarter ended September 30, 2022, was $22.7 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750284/000155837022016899/0001558370-22-016899-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"$22.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}